Applications of QSAR to Enzymes Involved in Toxicology

Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals

Volumn , Issue , 2006, Pages 277-293

  Ekins, Sean ^a  

^a ACT LLC   (United States)

Author keywords

QSAR application to enzymes in toxicology; QSAR for enzymes; QSAR model predictions

Indexed keywords

EID: 67349129830     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470145890.ch10     Document Type: Chapter

References (120)

1. Leibman KC. Drug metabolism: Prospects for the future. Drug Metab Rev 1979;10:299-309.
2. Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, et al. Drug-drug interactions related to hospital admissions in older adults: A prospective study of 1000 patients. JAGS 1996;44:944-8.
3. Yee JL, Hasson NK, Schreiber DH. Drug-related emergency department visits in an elderly veteran population. An Pharmacother 2005;39:1990-4.
4. Pezalla E. Preventing adverse drug reactions in the general population. Manag Care Interface 2005;18:49-52.
5. Zhan C, Correa-de-Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW, et al. Suboptimal prescribing in elderly outpatients: Potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc 2005;53:262-7.
6. Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalisation and mortality: A population-based study of the very old. Drugs Aging 2005;22:69-82.
7. Austel V, Kutter E. Absorption, distribution, and metabolism of drugs. In: Topliss JG, editor, Quantitative structure-activity relationships of drugs. New York: Academic Press, 1983. p. 437-96.
8. Smith DA, Obach RS. Seeing through the mist: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 2005;33:1409-17.
9. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharm Exp Ther 1997;283:1552-62.
10. Ekins S. Computer methods for predicting drug metabolism. In: Ekins S, editor, Computer applications in pharmaceutical research and development. Hoboken, NJ: Wiley, 2006. p. 445-68.
11. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201-8.
12. de Graaf C, Vermeulen NP, Feenstra KA. Cytochrome P450 in silico: An integrative modeling approach. J Med Chem 2005;48:2725-55.
13. Hansch C. Quantitative relationships between lipophilic character and drug metabolism. Drug Metab Rev 1972;1:1-14.
14. Hansch C. The QSAR paradigm in the design of less toxic molecules. Drug Metab Rev 1984;15:1279-94.
15. Hansch C, Lien EJ, Helmer F. Structure-activity correlations in the metabolism of drugs. Arch Biochem Biophys 1968;128:319-30.
16. Hansch C, Zhang L. Quantitative structure-activity relationships of cytochrome P-450. Drug Metab Rev 1993;25:1-48.
17. Lewis DFV. Quantitative structure activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). Drug Metab Rev 1997;29:589-650.
18. Lewis DFV. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Pharmacol 2000;60:293-306.
19. Lewis DFV. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 2000;144:197-203.
20. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem Bio Interact 1998;115:175-99.
21. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS. Erratum to structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem Biol Interact 1999;117:187.
22. Lewis DF, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Disc Today 2004;9:530-7.
23. Ekins S, Swaan PW. Development of computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX. Rev Comp Chem 2004;20:333-15.
24. Fuhr U, Strobl G, Manaut F, Anders E-M, Sorgel F, Lopez-de-brinas E, et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993;43:191-9.
25. Jones JP, Korzekwa KR. Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily. New York: Academic Press, 1996.
26. Locuson CW, Wahlstrom JL. Three-dimensional quantitative structure-activity relationship analysis of cytochromes p450: Effect of incorporating higher-affinity ligands and potential new applications. Drug Metab Dispos 2005;33:873-8.
27. Balakin KV, Ekins S, Bugrim A, Ivanenkov YA, Korolev D, Nikolsky Y, et al. Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos 2004;32:1183-9.
28. Balakin KV, Ekins S, Bugrim A, Ivanenkov YA, Korolev D, Nikolsky Y, et al. Quantitative structure-metabolism relationship modeling of the metabolic N-dealkylation rates. Drug Metab Dispos 2004;32:1111-20.
29. Yao H, Costache AD, Sem DS. Chemical proteomic tool for ligand mapping of CYP antitargets: An NMR-compatible 3D QSAR descriptor in the heme-based coordinate system. J Chem Inf Comput Sci 2004;44:1456-65.
30. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. An Rev Pharmacol Toxicol 2000;40:581-616.
31. Ethell BT, Ekins S, Wang J, Burchell B. Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos 2002;30:734-8.
32. Sorich MJ, McKinnon RA, Miners JO, Winkler DA, Smith PA. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. J Med Chem 2004;47:5311-17.
33. Smith PA, Sorich M, McKinnon R, Miners JO. QSAR and pharmacophore modelling approaches for the prediction of UDP-glucuronosyltransferase substrate selectivity and binding. Pharmacologist 2002;44(Suppl).
34. Sorich M, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 2002;12:635-45.
35. Smith PA, Sorich MJ, McKinnon RA, Miners JO. In silico insights: Chemical and structural characteristics associated with uridine diphosphate-glucuronosyl-transferase substrate selectivity. Clin Exp Pharmacol Physiol 2003;30:836-40.
36. Smith PA, Sorich MJ, McKinnon RA, Miners JO. Pharmacophore and quantitative structure-activity relationship modeling: Complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem 2003;46:1617-26.
37. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. Predicting human drug glucuronidation parameters: Application of in vitro and in silico modeling approaches. An Rev Pharmacol Toxicol 2004;44:1-25.
38. Smith PA, Sorich MJ, Low LS, McKinnon RA, Miners JO. Towards integrated ADME prediction: Past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. J Mol Graph Model 2004;22:507-17.
39. Sorich MJ, Miners JO, McKinnon RA, Smith PA. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol 2004;65:301-8.
40. Dajani R, Cleasby A, Neu M, Wonacott AJ, Jhoti H, Hood AM, et al. X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. J Biol Chem 1999;53:37862-8.
41. Gamage NU, Duggleby RG, Barnett AC, Tresillian M, Latham CF, Liyou NE, et al. Structure of a human carcinogen-converting enzyme, SULT1A1. J Biol Chem 2003;278:7655-62.
42. Ekins S, de Groot M, Jones JP. Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 2001;29:936-44.
43. Ekins S, VandenBranden M, Ring BJ, Wrighton SA. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997;7:165-79.
44. Ekins S, VandenBranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, et al. Further characterization of the expression and catalytic activity of human CYP2B6. J Pharm Exp Ther 1998;286:1253-9.
45. Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, VandenBranden M, et al. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J Pharm Exp Ther 1999;288:21-9.
46. Ekins S, Bravi G, Wikel JH, Wrighton SA. Three dimensional quantitative structure activty relationship (3D-QSAR) analysis of CYP3A4 substrates. J Pharm Exp Ther 1999;291:424-33.
47. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999;9:477-89.
48. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three and four dimensional-quantitative structure activity relationship analyses of CYP3A4 inhibitors. J Pharm Exp Ther 1999;290:429-38.
49. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 2000;28:994-1002.
50. Snyder R, Sangar R, Wang J, Ekins S. Three dimensional quantitative structure activity relationship for CYP2D6 substrates. Quant Struct-Act Rel 2002;21:357-68.
51. Ekins S, Stresser DM, Williams JA. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 2003;24:191-6.
52. Ekins S, Wrighton SA. Application of in silico approaches to predicting drug-drug interactions: A commentary. J Pharm Tox Meth 2001;44:1-5.
53. Asikainen A, Tarhanen J, Poso A, Pasanen M, Alhava E, Juvonen RO. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol In Vitro 2003;17:449-55.
54. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: Practical considerations. Drug Metab Rev 2000; 32:339-61.
55. Ekins S, Wrighton SA. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 1999;31:719-54.
56. Ekins S, Berbaum J, Harrison RK. Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab Dispos 2003;31:1077-80.
57. Locuson CW, 2nd, Wahlstrom JL, Rock DA, Rock DA, Jones JP. A new class of CYP2C9 inhibitors: Probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos 2003;31:967-71.
58. Locuson CW II, Rock DA, Jones JP. Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry 2004;43:6948-58.
59. Locuson CW, 2nd, Suzuki H, Rettie AE, Jones JP. Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. J Med Chem 2004;47:6768-76.
60. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate-models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998;37:4137-47.
61. Ekins S, Ring BJ, Binkley SN, Hall SD, Wrighton SA. Autoactivation and activation of cytochrome P450s. Int J Clin Pharmacol Ther 1998;36:642-51.
62. Atkins WM. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. An Rev Pharmacol Toxicol 2005;45:291-310.
63. Bauman JN, Goosen TC, Tugnait M, Peterkin V, Hurst SI, Menning LC, et al. Udp-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes. Drug Metab Dispos 2005;33:1349-54.
64. Egnell AC, Houston JB, Boyer CS. Predictive models of CYP3A4 heteroactivation: In vitro-in vivo scaling and pharmacophore modelling. J Pharmacol Exp Ther 2005;312:926-37.
65. Egnell AC, Eriksson C, Albertson N, Houston B, Boyer S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 2003;307:878-87.
66. Wang Q, Halpert JR. Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab Dispos 2002;30:86-95.
67. Jones JP, Mysinger M, Korzekwa KR. Computational models for cytochrome P450: A predictive electronic model for aromatic oxidation and hydrogen abstraction. Drug Metab Dispos 2002;30:7-12.
68. Singh SB, Shen LQ, Walker MJ, Sheridan RP. A model for likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem 2003;46:1330-6.
69. Csanady GA, Laib JG. Metabolic transformation of halogenated and other alkenes-a theoretical approach: Estimation of metabolic reactivities for in vivo conditions. Toxicology 1995;75:217-23.
70. Yin H, Anders MW, Korzekwa KR, Higgins L, Thummel KE, Kharasch ED, et al. Designing safer chemicals: Predicting the rates of metabolism of haloge-nated alkanes. Proc Natl Acad Sci USA 1995;92:11076-80.
71. Korzekwa K, Ewing TJ, Kocher JP, Carlson TJ. Models for cytochrome P450-mediated metabolism. In: Borchardt RT, Kerns EH, Lipinski CA, Thakker DR, Wang B, editors, Pharmaceutical profiling in drug discovery for lead selection. AAPS Press, 2004. Arlington, VA. p. 69-80.
72. Bursi R, de Gooyer ME, Grootenhuis A, Jacobs PL, van der Louw J, Leysen D. (Q)SAR study on the metabolic stability of steroidal androgens. J Mol Graph Model 2001;19:552-6.
73. Berellini G, Cruciani G, Mannhold R. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. J Med Chem 2005;48:4389-99.
74. Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C, Howe T, et al. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 2005;48:6970-9.
75. Zhou D, Afzelius L, Grimm SW, Andersson TB, Zauhar RJ, Zamora I. Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab Dispos 2006;34:976-83.
76. Korolev D, Balakin KV, Nikolsky Y, Kirillov E, Ivanenkov YA, Savchuk NP, et al. Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J Med Chem 2003;46:3631-43.
77. Young SS, Ekins S, Lambert C. So many targets, so many compounds, but so few resources. Curr Drug Disc 2002;Dec:17-22.
78. Young SS, Gombar VK, Emptage MR, Cariello NF, Lambert C. Mixture deconvolution and analysis of Ames mutagenicity data. Chemom Intell Lab Sys 2002;60:5-11.
79. Li AP. A review of the common properties of drugs with idiosyncratic hepato-toxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002;142:7-23.
80. Williams DP, Park BK. Idiosyncratic toxicity: The role of toxicophores and bioactivation. Drug Discov Today 2003;8:1044-50.
81. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 2003;8:832-7.
82. Ekins S, Andreyev S, Ryabov A, Kirillov E, Rakhmatulin EA, Sorokina S, et al. A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos 2006;34:495-503.
83. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov Today 2004;9:276-85.
84. Ekins S, Giroux C. Computers and systems biology for pharmaceutical research and development. In: Ekins S, editor, Computer applications in pharmaceutical research and development. Hoboken, NJ: Wiley, 2006. p. 139-65.
85. Chang C, Ekins S, Bahadduri P, Swaan PW. Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Del Rev 2006;58(12-13):1431-30.
86. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006;34:1976-84.
87. Lill MA, Dobler M, Vedani A. Prediction of small-molecule binding to cytochrome P450 3A4: Flexible docking combined with multidimensional QSAR. ChemMedChem 2006;6:73-81.
88. Mao B, Gozalbes R, Barbosa F, Migeon J, Merrick S, Kamm K, et al. QSAR modeling of in vitro inhibition of cytochrome P450 3A4. J Chem Inf Model 2006;46:2125-34.
89. Kim YM, Ziegler DM. Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab Dispos 2000;28:1003-6.
90. Soffers AEMF, Ploeman JHTM, Moonen MJH, Wobbes T, van Ommen B, Vervoort J, et al. Regioselectivity and quantitative structure-activity relationships for the conjugation of a series of fluoronitrobenzenes by purified glutathione S-transferase enzymes from rat and man. Chem Res Toxicol 1996;9:638-46.
91. Medvedev AE, Veselovsky AV, Shvedov VI, Tikhonova OV, Moskvitina TA, Fedotova OA, et al. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis. J Chem Inf Comput Sci 1998;38:1137-44.
92. Miller JR, Edmondson DE. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 1999;38:13670-83.
93. Chimenti F, Bolasco A, Manna F, Secci D, Chimenti P, Granese A, et al. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr Med Chem 2006;13:1411-28.
94. Carrieri A, Carotti A, Barreca ML, Altomare C. Binding models of reversible inhibitors to type-B monoamine oxidase. J Comput Aided Mol Des 2002;16:769-78.
95. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Meth 2000;44:251-72.
96. Cavalli A, Greco G, Novellino E, Recanatini M. Linking CoMFA and protein homology models of enzyme-inhibitor interactions: An application to non-steroidal aromatase inhibitors. Bioorg Med Chem 2000;8:2771-80.
97. Leonetti F, Favia A, Rao A, Aliano R, Paluszcak A, Hartmann RW, et al. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J Med Chem 2004;47:6792-803.
98. Nagy PI, Tokarski J, Hopfinger AJ. Molecular shape and QSAR analyses of a famiy of substituted dichlorodiphenyl aromatase inhibitors. J Chem Inf Comput Sci 1994;34:1190-7.
99. Recanatini M. Comparative molecular field analysis of nonsteroidal aromatase inhibitors related to fadrozole. J Comp Aided Mol Des 1996;10:74-82.
100. Recanatini M, Cavalli A. Comparative molecular field analysis of non-steroidal aromatase inhibitors: An extended model for two different structural classes. Bioorg Med Chem 1998;6:377-88.
101. Sonnet P, Dallemagne P, Guillon J, Enguehard C, Stiebing S, Tanguy J, et al. New aromatase inhibitors, synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives. Bioorg Med Chem 2000;8:945-55.
102. Schuster D, Laggner C, Steindl TM, Palusczak A, Hartmann RW, Langer T. Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J Chem Inf Model 2006;46:1301-11.
103. Wadkins RM, Hyatt JL, Yoon KJ, Morton CL, Lee RE, Damodaran K, et al. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 2004;65:1336-43.
104. Wadkins RM, Hyatt JL, Wei X, Yoon KJ, Wierdl M, Edwards CC, et al. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem 2005;48:2906-15.
105. Knaak JB, Dary CC, Power F, Thompson CB, Blancato JN. Physicochemical and biological data for the development of predictive organophosphorus pesticide QSARs and PBPK/PD models for human risk assessment. Crit Rev Toxicol 2004;34:143-207.
106. Buchwald P, Bodor N. Quantitative structure-metabolism relationships: Steric and non steric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 1999;42:5160-8.
107. McElroy NR, Jurs PC, Morisseau C, Hammock BD. QSAR and classification of murine and human epoxide hydrolase inhibition by urea-like compounds. J Med Chem 2003;46:1066-80.
108. Nakagawa Y, Wheelock CE, Morisseau C, Goodrow MH, Hammock BG, Hammock BD. 3D-QSAR analysis of inhibition of murine soluble epoxide hydrolase (MsEH) by benzoylureas, arylureas, and their analogues. Bioorg Med Chem 2000;8:2663-73.
109. Kim EJ, Kim KS, Shin WH. Electrophysiological safety of DW-286a, a novel fluoroquinolone antibiotic agent. Hum Exp Toxicol 2005;24:19-25.
110. Hansch C, Klein T, McClarin J, Langridge R, Cornell NW. A quantitative struc-ture-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase. J Med Chem 1986;29:615-20.
111. Kutsenko AS, Kuznetsov DA, Poroikov VV, Tumanian VG. Mapping of active site of alcohol dehydrogenase with low-molecular ligands. Bioorg Khim 2000;26:179-86.
112. Skibo EB, Xing C, Dorr RT. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: Structure-activity relationships for cytotoxicity and antitumor activity. J Med Chem 2001;44:3545-62.
113. Khadikar P, Jaiswal M, Gupta M, Mandloi D, Sisodia RS. QSAR studies on 1,2-dithiole-3-thiones: Modeling of lipophilicity, quinone reductase specific activity, and production of growth hormone. Bioorg Med Chem Lett 2005;15:1249-55.
114. Pouplana R, Lozano JJ, Perez C, Ruiz J. Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs. J Comput Aided Mol Des 2002;16:683-709.
115. Taskinen J, Ethell BT, Pihlavisto P, Hood AM, Burchell B, Coughtrie MW. Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models. Drug Metab Dispos 2003;31:1187-97.
116. Sipila J, Taskinen J. CoMFA modeling of human catechol O-methyltransferase enzyme kinetics. J Chem Inf Comput Sci 2004;44:97-104.
117. Lautala P, Ulmanen I, Taskinen J. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol 2001;59:393-402.
118. Chen D, Wang CY, Lambert JD, Ai N, Welsh WJ, Yang CS. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: Struc-ture-activity relationship and molecular-modeling studies. Biochem Pharmacol 2005;69:1523-31.
119. Ames MM, Selassie CD, Woodson LC, Van Loon JA, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: Structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J Med Chem 1986;29:354-8.
120. Mesangeau C, Yous S, Chavatte P, Ferry G, Audinot V, Boutin JA, et al. Design, synthesis and in vitro evaluation of novel benzo[b]thiophene derivatives as serotonin N-acetyltransferase (AANAT) inhibitors. J Enzyme Inhib Med Chem 2003;18:119-25.